Flavopiridol: The first cyclin-dependent kinase inhibitor in human clinical trials

Investigational New Drugs

Volumn 17, Issue 3, 1999, Pages 313-320

  Senderowicz, Adrian M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cell cycle; Chemotherapy; Clinical trials; Cyclin D1; Cyclin dependent kinases; Flavonoids; Flavopiridol; Protein kinases; Signal transduction

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CLINICAL TRIAL; COLON CARCINOMA; DIARRHEA; ENZYME INHIBITION; HUMAN; HYPOTENSION; KIDNEY CARCINOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; STOMACH CARCINOMA;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CLINICAL TRIALS; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; NEOPLASMS; PIPERIDINES;

EID: 0033375469     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006353008903     Document Type: Article

References (55)

1. Sherr CJ: Cancer cell cycles. Science 274: 1672, 1996
2. Hatakeyama M, Weinberg RA: The role of RB in cell cycle control. Prog Cell Cycle Res 1: 9, 1995
3. Morgan DO, Fisher RP, Espinoza FH, Farrell A, Nourse J, Chamberlin H, Jin P: Control of eukaryotic cell cycle progression by phosphorylation of cyclin-dependent kinases [In Process Citation]. Cancer J Sci Am 4 Suppl 1: S77, 1998
4. Morgan DO: Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13: 261, 1997
5. Rickert P, Seghezzi W, Shanahan F, Cho H, Lees E: Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II. Oncogene 12: 2631, 1996
6. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA: A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92: 451, 1998
7. Grana X, De Luca A, Sang N, Fu Y, Claudio PP, Rosenblatt J, Morgan DO, Giordano A: PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro. Proc Natl Acad Sci USA 91: 3834, 1994
8. MacLachlan TK, Sang N, Giordano A: Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 5: 127, 1995
9. Edwards MC, Wong C, Elledge SJ: Human cyclin K, a novel RNA polymerase II-associated cyclin possessing both carboxy-terminal domain kinase and Cdk-activating kinase activity. Mol Cell Biol 18: 4291, 1998
10. Peng J, Zhu Y. Milton JT, Price DH: Identification of multiple cyclin subunits of human P-TEFb. Genes Dev 12: 755, 1998
11. Kaldis P, Russo AA, Chou HS, Pavletich NP, Solomon MJ: Human and Yeast Cdk-activating Kinases (CAKs) Display Distinct Substrate Specificities. Mol Biol Cell 9: 2545, 1998
12. Tassan JP, Schultz SJ, Bartek J, Nigg EA: Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase). J Cell Biol 127: 467, 1994
13. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501, 1999
14. Zhang HS, Postigo AA, Dean DC: Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition. Cell 97: 53, 1999
15. Dyson N: The regulation of E2F by pRB-family proteins. Genes Dev 12: 2245, 1998
16. DelSal G, Loda M, Pagano M: Cell cycle and cancer: critical events at the G1 restriction point. Crit Rev Oncog 7: 127, 1996
17. Grana X, Reddy EP: Cell cycle control in mammalian cells: role of cyclins, dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKls). Oncogene 11:211, 1995
18. Pardee AB: Multiple molecular levels of cell cycle regulation. J Cell Biochem 54: 375, 1994
19. Pines J: Cyclins and cyclin-dependent kinases: theme and variations. Adv Cancer Res 66: 181, 1995
20. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323, 1995
21. Sausville EA, Zaharevitz DW, Gussio R, Meijer L, Leost M, Kunick C, Schultz R, Lahusen T, Headlee D, Stinson S, Arbuck S, Senderowicz AM: Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target. Pharmacol Ther 82: 285, 1999
22. Sedlacek HH, Czech J, Naik R, Kaur G, Worland P, Losiewicz M, Parker B, Carlson B, Smith A, Senderowicz A, Sausville E: Flavopiridol (L86-8275, NSC-649890), a new kinase inhibitor for tumor therapy. Inter J Oncol 9: 1143, 1996
23. Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, Czech J, Naik R, Sausville E: Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 84: 1736, 1992
24. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ: Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56: 2973, 1996
25. Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland PJ: Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 201: 589, 1994
26. Carlson B, Pearlstein R, Naik R, Sedlacek H, Sausville E, Worland P: Inhibition of CDK2, CDK4 and CDK7 by flavopiridol and structural analogs. Proceedings of the American Association for Cancer Research, 1996
27. Worland PJ, Kaur G, Stetler-Stevenson M, Sebers S, Sartor O, Sausville EA: Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased HI kinase activity. Biochem Pharmacol 46: 1831, 1993
28. De Azevedo WF, Jr, Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH: Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase, Proc Natl Acad Sci USA 93: 2735, 1996
29. Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A: Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 55: 975, 1995
30. Gansauge S, Gansauge F, Ramadani M, Stobbe H, Rau B, Harada N, Beger HG: Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 57: 1634, 1997
31. Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, MJ OH, Lu X: High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94: 6380, 1997
32. Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R, Albanese C, Sausville EA, Senderowicz AM: Downregulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res (in press), 1999
33. Gray NS, Wodicka L, Thunnissen AM, Norman TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, LeClerc S, Meijer L, Kim SH, Lockhart DJ, Schultz PG: Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281: 533, 1998
34. Arguello F, Alexander M, Sterry J, Tudor G, Smith E, Kalavar N, Greene J, Koss W, Morgan D, Stinson S, Siford T, Alvord W, Labansky R, Sausville E: Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppresion, and has potent antitumor activity in vivo against human and leukemia xenografts. Blood 91: 2482, 1998
35. Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen FL, Flinn IW, Diehl LF, Sausville E, Grever MR: Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 92: 3804, 1998
36. Parker BGK, Nieves-Neira W, Taimi M, Kolhagen G, Shimizu T, Pommier Y, Sausville E, Senderowicz AM: Early induction of Apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 91: 458, 1998
37. Konig A, Schwartz GK, Mohammad RM, Al-Katib A, Gabrilove JL: The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 90: 4307, 1997
38. Patel V, Senderowicz AM, Pinto D, Igishi T, Raffeld M, Quintanilla-Martinet L, Ensley JF, Sausville EA, Gutkind JS: Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 102: 1674, 1998
39. Chien M, Astumian M, Liebowitz D, Rinker-Schaeffer C, Stadler W: In vitro evaluation of flavopinidol, a novel cell cycle inhibitor, in bladder cancer. Cancer Chemother Pharmacol 44: 81, 1999
40. Schrump DS, Matthews W, Chen GA, Mixon A, Altorki NK: Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells [In Process Citation]. Clin Cancer Res 4: 2885, 1998
41. Bible KC, Kaufmann SH: Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 56: 4856, 1996
42. Park DS, Farinelli SE, Greene LA: Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons. J Biol Chem 271: 8161, 1996
43. Brusselbach S, Nettelbeck DM, Sedlacek HH, Muller R: Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells. Int J Cancer 77: 146, 1998
44. Kerr JS, Wexler RS, Mousa SA, Robinson CS, Wexler EJ, Mohamed S, Voss ME, Devenny JJ, Czerniak PM, Gudzelak A, Jr, Slee AM: Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors [In Process Citation]. Anticancer Res 19: 959, 1999
45. Melillo G, Sausville E, Cloud K, Lahusen T, Varresio L, Senderowicz A: Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of VEGF expression in human monocytes. Cancer Research (in press), 1999
46. Lee HR, Chang TH, Tebalt MJ, 3rd, Senderowicz AM, Szabo E: Induction of differentiation accompanies inhibition of cdk2 in a non-small cell lung cancer cell line [In Process Citation]. Int J Oncol 15: 161, 1999
47. Schwartz G, Farsi K, Maslak P, Kelsen D, Spriggs D: Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clinical Cancer Research 3: 1467, 1997
48. Bible KC, Kaufmann SH: Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 57: 3375, 1997
49. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG, Sausville EA: Phase I trial of continuous infusion flavopiridol, a novel cyclin- dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16: 2986, 1998
50. Jager W, Zembsch B, Wolschann P, Pittenauer E, Senderowicz AM, Sausville E, Sedlacek H, Graf J, Thalhammer T: Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver. Life Sci 62 1861-1873: 1861, 1998
51. Lush R, Stinson S, Senderowicz A, Hill K, Feuer J, Headlee D, Figg WES: Flavopiridol pharmacokinetics suggest entoerohepatic circulation. Clinical Pharmacology and Therapeutics 61: 145, 1997
52. Drees M, Dengler W, Roth T, Labonte H, Mayo J, Malspeis L, Grever M, Sausville E, Fiebig H: Flavopiridol (L86-8275): Selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clinical Cancer Research 32: 273, 1997
53. Thomas J, Cleary J, Tutsch K, Arzoomanian R, Alberti D, Simon K, Feierabend D, Morgan K, Wilding G: Phase I clinical and pharmacokinetic trial of flavopiridol. Proc eighty-eightieth Annual Meeting of the American Association of Cancer Research. San Diego, CA, 1997
54. Shenfeld M, Senderowicz AM, Sausville EA, Ke B: A novel chemotherapeutic agent, flavopiridol, modulates intestinal epithelial chloride secretion. Gastroenterology 112: 404, 1997
55. Wright J, Blatner GL, Cheson BD: Clinical trials referral resource. Clinical trials of flavopiridol. Oncology (Huntingt) 12: 1018, 1998